BioAge Labs Inc. (BIOA) vs Galectin Therapeutics Inc. (GALT)
A side-by-side comparison of BioAge Labs Inc. and Galectin Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BIOA
BioAge Labs Inc.
$6.31HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT
GALT
Galectin Therapeutics Inc.
$3.68HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT
Total return — BIOA vs GALT
growth of $100 · dividends reinvested · last 2yBIOA -65.3% (-41.1%/yr)GALT +39.7% (+18.2%/yr)GALT compounded faster over this window
BIOA GALT
BIOA vs GALT: by the numbers
- •GALT is the larger company ($242M vs $237M market cap).
- •Both run net losses; GALT's is the smaller (0.00% vs -912.25% net margin).
Metrics side by side
Valuation
| Metric | BIOA | GALT |
|---|---|---|
| P/S ratio | 22.92 | N/A |
| P/B ratio | 0.63 | N/A |
Profitability
| Metric | BIOA | GALT |
|---|---|---|
| Gross margin | 99.39% | 0.00% |
| Operating margin | -1026.28% | 0.00% |
| Net margin | -912.25% | 0.00% |
| ROE | -25.20% | N/A |
| ROIC | -28.14% | -1718.59% |
Growth (annualized)
| Metric | BIOA | GALT |
|---|---|---|
| Total return CAGR (5Y) | N/A | 0.60% |
Go deeper
Dig into the metrics
BioAge Labs ROEGalectin Therapeutics ROEBioAge Labs operating marginGalectin Therapeutics operating marginBioAge Labs revenue growthGalectin Therapeutics revenue growthBioAge Labs free cash flowGalectin Therapeutics free cash flow
BioAge Labs & Galectin Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.